Answers are grounded in this paper and cite their sources.
Composite hydrogel demonstrates improved cartilage regeneration in vitro, highlighting its potential for minimally invasive therapies.
With the growing global burden of cartilage degeneration in aging populations and the limitations of conventional surgical interventions, tissue-engineered hydrogels have emerged as a transformative strategy for functional cartilage regeneration. Here, we report an innovative bioinspired composite hydrogel fabricated through carbodiimide-mediated crosslinking of silk fibroin (SF) and hyaluronic acid (HA) using 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC)/N-hydroxysuccinimide (NHS) in MES buffer. The engineered hydrogel exhibited an optimally interconnected porous architecture (pore size: 50-100 μm), tunable compressive modulus ( 86.51 KPa mimicking native cartilage), and swelling performance (570 ± 15%), addressing critical requirements for minimally invasive delivery and mechanical stability. Comprehensive in vitro characterization demonstrated exceptional cytocompatibility, with close to 100% hBMSC viability over 7 days. Most notably, the SF/HA hydrogel significantly promoted chondrogenic differentiation, as evidenced by: (1) 1.8 fold increased in progressive glycosaminoglycan (GAG) deposition (Alcian blue staining), (2) upregulation of SOX9, COL2, and AGG gene expression (RT-qPCR, 1.4, 0.4 and 1.3 fold vs. control), and (3) enhanced type II collagen synthesis (Western blot). These results demonstrate the potential of SF/HA hydrogel for cell-based cartilage repair and osteoarthritis therapy.
No takes yet. Share an insight, caveat, or question.
Song et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: